Abivax S.A.
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Abivax S.A. sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Abivax S.A.: 6 sponsored US clinical trials, 2 recruiting.
Abivax S.A. sponsors 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 3 completed. 3 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Moderately to Severely Active Crohn Disease, with 1 trials.
Upper-quartile sponsor footprint
Abivax S.A. sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
NCT06456593
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
NCT03897543
ABTECT - Maintenance
NCT05535946
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
NCT05507216
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
NCT05507203
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
NCT03760003
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 3 |
Therapeutic Areas
What is open in the Abivax S.A. pipeline
2 recruiting of 6 indexed (33% open); 3 completed (50%).
Phase mix: 3 late (III/IV) vs 3 early (I/II) (balanced across stages).
Top condition: Moderately to Severely Active Crohn Disease (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Abivax S.A.: open-pipeline peers nationwide
Peers matched on 6 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Abivax S.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Actuated Medical · 33% recruiting · 3 trials
- Adagio Medical · 33% recruiting · 3 trials
Related
What to do with this Abivax S.A. page
6 registered trials is a research-attention snapshot, not an endorsement of Abivax S.A. or any single study.
- 2 of Abivax S.A.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Moderately to Severely Active Crohn Disease is the condition Abivax S.A. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Moderately to Severely Active Crohn Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Abivax S.A. pipeline card: 6 registered trials from official public datasets.Report a data error.